Sabra Health Care REIT (SBRA) Insider Ann Kono Buys 8,310 Shares
Insider Ann Kono purchased shares of Sabra Health Care REIT, reflecting continued confidence among insiders.
Reviewed by automated data checks against the source filing. How we make and check alerts
Ann Kono bought 8,310 shares of Sabra Health Care REIT, Inc. ($SBRA) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SBRA is up 5.8% after 1 week, up 11.4% after 1 month and up 8.8% to date (from the $17.78 close on Jun 17, 2026).
SBRA
Sabra Health Care REIT, Inc.
Key Points
- On June 17, 2026, Ann Kono acquired 8,310 shares of Sabra Health Care REIT (SBRA) at a price of $18.12 each, totaling about $150,000.
- This purchase follows multiple insider transactions on the same day, including shares bought by Craig Barbarosh, Jeffrey Malehorn, and others, each acquiring 8,310 shares.
- Analysts maintain a consensus rating of 'buy' for Sabra Health Care REIT, with a mean price target of $22.79, as of October 13, 2026.
Get $SBRA trade alerts by text
We text you when insiders, Congress or big funds trade $SBRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Sabra Health Care REIT, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Sabra Health Care REIT, Inc.
On June 17, 2026, Ann Kono bought 8,310 shares of Sabra Health Care REIT, Inc. (SBRA) on the NasdaqGS at a price of $18.12 each. This purchase is valued at about $150,000. It reflects a pattern of insider confidence, as several other executives made similar moves on the same day.
A Wave of Insider Purchases
Kono's acquisition is part of a broader wave of insider buying at Sabra. On June 17, Craig Barbarosh, Jeffrey Malehorn, Michael Foster, Catherine Cusack, and Lynne Katzmann each purchased 8,310 shares of the company. These transactions suggest a strong belief in the company's future, as multiple insiders are investing in the stock simultaneously.
Analysts Set New Price Targets
Analysts have remained positive about Sabra Health Care REIT. On October 13, 2026, UBS maintained its 'Neutral' rating with a price target of $20, while Barclays also kept its 'Equal-Weight' rating but lowered its target to $21. The consensus rating for Sabra is 'buy,' with a mean price target set at $22.79 based on 14 analyst opinions. This indicates that experts see potential for growth in the stock.
How Sabra Health Care REIT, Inc. Stock Has Traded
As of the close on June 17, SBRA traded at $18.12, which is close to its 52-week low of $17.17. The stock has a 52-week high of $22.77. This recent buying activity by insiders may suggest they believe the stock is undervalued at current levels.
What Sabra Health Care REIT, Inc. Does
Sabra Health Care REIT, Inc. is a real estate investment trust that invests in properties serving the healthcare industry across the U.S. and Canada. The recent insider purchases could indicate confidence in the company's ability to navigate the healthcare real estate market successfully.
What's Ahead for Sabra Health Care REIT, Inc.
Investors will be watching for updates as Sabra prepares for its next earnings report on November 4, 2026. The recent insider activity reflects past positions as reported in the filings, which may not represent current holdings. It's worth noting that these transactions occurred amid fluctuating analyst ratings and targets, suggesting a dynamic market environment.
Related Filing Alerts
Source: Ann Kono's Form 4 filing on $SBRA (Jun 17, 2026). Find the original filing: SBRA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts